Charles M Rice

List of Publications by Year in Descending Order

198 papers	25,050 citations	65 h-index	158 g-index
209 ext. papers	31,573 ext. citations	16.3 avg, IF	6.97 L-index

#	Paper	IF	Citations
198	System-wide transcriptome damage and tissue identity loss in COVID-19 patients.. *Cell Reports Medicine*, **2022**, 3, 100522	18	2
197	Conserved Neutralizing Epitopes on the N-Terminal Domain of Variant SARS-CoV-2 Spike Proteins. **2022**,		1
196	Lung type II alveolar epithelial cells collaborate with CCR2 inflammatory monocytes in host defense against poxvirus infection.. *Nature Communications*, **2022**, 13, 1671	17.4	0
195	Proteomic elucidation of the targets and primary functions of the picornavirus 2A protease.. *Journal of Biological Chemistry*, **2022**, 101882	5.4	1
194	Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins.. *Immunity*, **2022**,	32.3	10
193	The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies.. *Proceedings of the National Academy of Sciences of the United States of America*, **2022**, 119, e2200413119	11.5	3
192	Replication and single-cycle delivery of SARS-CoV-2 replicons. *Science*, **2021**, 374, 1099-1106	33.3	7
191	A CRISPR Activation Screen Identifies an Atypical Rho GTPase That Enhances Zika Viral Entry. *Viruses*, **2021**, 13,	6.2	1
190	E3 ubiquitin ligase Mindbomb 1 facilitates nuclear delivery of adenovirus genomes. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	4
189	Quantitative measurements of early alphaviral replication dynamics in single cells reveals the basis for superinfection exclusion. *Cell Systems*, **2021**, 12, 210-219.e3	10.6	5
188	Decoupling expression and editing preferences of ADAR1 p150 and p110 isoforms. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	5
187	Broad and potent neutralizing human antibodies to tick-borne flaviviruses protect mice from disease. *Journal of Experimental Medicine*, **2021**, 218,	16.6	6
186	Argonaute-CLIP delineates versatile, functional RNAi networks in Aedes aegypti, a major vector of human viruses. *Cell Host and Microbe*, **2021**, 29, 834-848.e13	23.4	1
185	Naturally enhanced neutralizing breadth to SARS-CoV-2 after one year **2021**,		19
184	Fc-engineered antibody therapeutics with improved efficacy against COVID-19 **2021**,		4
183	DRUL for school: Opening Pre-K with safe, simple, sensitive saliva testing for SARS-CoV-2. *PLoS ONE* , **2021**, 16, e0252949	3.7	0
182	Pathogenesis, MicroRNA-122 Gene-Regulation, and Protective Immune Responses After Acute Equine Hepacivirus Infection. *Hepatology*, **2021**, 74, 1148-1163	11.2	2

181	Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient-Derived Xenografts and Direct-from-Patient Screening. *Cancer Discovery*, **2021**, 11, 2544-2563	24.4	2
180	Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. *Nature*, **2021**, 595, 426-431	50.4	247
179	Profiling SARS-CoV-2 HLA-I peptidome reveals T cell epitopes from out-of-frame ORFs. *Cell*, **2021**, 184, 3962-3980.e17	56.2	26
178	Enhanced SARS-CoV-2 neutralization by dimeric IgA. *Science Translational Medicine*, **2021**, 13,	17.5	178
177	TMEM41B Is a Pan-flavivirus Host Factor. *Cell*, **2021**, 184, 133-148.e20	56.2	62
176	Genome-Scale Identification of SARS-CoV-2 and Pan-coronavirus Host Factor Networks. *Cell*, **2021**, 184, 120-132.e14	56.2	166
175	A selectable, plasmid-based system to generate CRISPR/Cas9 gene edited and knock-in mosquito cell lines. *Scientific Reports*, **2021**, 11, 736	4.9	3
174	Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine. *Journal of Experimental Medicine*, **2021**, 218,	16.6	49
173	Functional interrogation of a SARS-CoV-2 host protein interactome identifies unique and shared coronavirus host factors. *Cell Host and Microbe*, **2021**, 29, 267-280.e5	23.4	65
172	Autoantibodies neutralizing type I IFNs are present in 4% of uninfected individuals over 70 years old and account for 20% of COVID-19 deaths. *Science Immunology*, **2021**, 6,	28	91
171	Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy. *Nature*, **2021**, 599, 465-470	50.4	27
170	Controlled Human Infection Model - Fast Track to HCV Vaccine?. *New England Journal of Medicine*, **2021**, 385, 1235-1240	59.2	0
169	Mouse characteristics that affect establishing xenografts from hepatocellular carcinoma patient biopsies in the United States.. *Cancer Medicine*, **2021**,	4.8	1
168	Liver-expressed and limit hepatitis C virus cross-species transmission to mice. *Science Advances*, **2020**, 6,	14.3	9
167	Identification of interferon-stimulated genes that attenuate Ebola virus infection. *Nature Communications*, **2020**, 11, 2953	17.4	11
166	A Combination of Human Broadly Neutralizing Antibodies against Hepatitis B Virus HBsAg with Distinct Epitopes Suppresses Escape Mutations. *Cell Host and Microbe*, **2020**, 28, 335-349.e6	23.4	25
165	Expansion, in vivo-ex vivo cycling, and genetic manipulation of primary human hepatocytes. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 1678-1688	11.5	21
164	Control of human hemoglobin switching by LIN28B-mediated regulation of BCL11A translation. *Nature Genetics*, **2020**, 52, 138-145	36.3	38

163	A combination of two human monoclonal antibodies limits fetal damage by Zika virus in macaques. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 7981-7989	11.5	11
162	Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. *ELife*, **2020**, 9,	8.9	784
161	Author response: Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants **2020**,		31
160	Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality. *Journal of Cell Biology*, **2020**, 219,	7.3	9
159	Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals **2020**,		60
158	Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses **2020**,		35
157	Enhanced SARS-CoV-2 Neutralization by Secretory IgA in vitro **2020**,		15
156	Functional interrogation of a SARS-CoV-2 host protein interactome identifies unique and shared coronavirus host factors **2020**,		15
155	Genome-scale identification of SARS-CoV-2 and pan-coronavirus host factor networks **2020**,		7
154	TMEM41B is a pan-flavivirus host factor **2020**,		4
153	Development of antibody-based assays for high throughput discovery and mechanistic study of antiviral agents against yellow fever virus. *Antiviral Research*, **2020**, 182, 104907	10.8	1
152	Defining the proteolytic landscape during enterovirus infection. *PLoS Pathogens*, **2020**, 16, e1008927	7.6	14
151	Downregulation of IGF2 expression in third trimester placental tissues from Zika virus infected women in Brazil. *Journal of Infection*, **2020**, 81, 766-775	18.9	1
150	Generation of a reporter yellow fever virus for high throughput antiviral assays. *Antiviral Research*, **2020**, 183, 104939	10.8	3
149	Equine pegiviruses cause persistent infection of bone marrow and are not associated with hepatitis. *PLoS Pathogens*, **2020**, 16, e1008677	7.6	6
148	RTP4 inhibits IFN-I response and enhances experimental cerebral malaria and neuropathology. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 19465-19474	11.5	10
147	Convergent antibody responses to SARS-CoV-2 in convalescent individuals. *Nature*, **2020**, 584, 437-442	50.4	1167
146	LY6E impairs coronavirus fusion and confers immune control of viral disease. *Nature Microbiology*, **2020**, 5, 1330-1339	26.6	98

145	Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. *Journal of Experimental Medicine*, **2020**, 217,	16.6	289
144	Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. *Science*, **2020**, 370,	33.3	994
143	Autoantibodies against type I IFNs in patients with life-threatening COVID-19. *Science*, **2020**, 370,	33.3	1090
142	Structural basis for Zika envelope domain III recognition by a germline version of a recurrent neutralizing antibody. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 9865-9875	11.5	5
141	Stem cell-derived polarized hepatocytes. *Nature Communications*, **2020**, 11, 1677	17.4	29
140	Defining the proteolytic landscape during enterovirus infection **2020**, 16, e1008927		
139	Defining the proteolytic landscape during enterovirus infection **2020**, 16, e1008927		
138	Defining the proteolytic landscape during enterovirus infection **2020**, 16, e1008927		
137	Defining the proteolytic landscape during enterovirus infection **2020**, 16, e1008927		
136	Inherited IL-18BP deficiency in human fulminant viral hepatitis. *Journal of Experimental Medicine*, **2019**, 216, 1777-1790	16.6	42
135	ZAPS stress granule localization is correlated with its antiviral activity and induced by virus replication. *PLoS Pathogens*, **2019**, 15, e1007798	7.6	28
134	HCV Molecular Virology and Animal Models. *Topics in Medicinal Chemistry*, **2019**, 29-68	0.4	1
133	Characterization of Novel Splice Variants of Zinc Finger Antiviral Protein (ZAP). *Journal of Virology*, **2019**, 93,	6.6	41
132	Identification and transcriptome analysis of erythroblastic island macrophages. *Blood*, **2019**, 134, 480-491	11.2	56
131	A protein-interaction network of interferon-stimulated genes extends the innate immune system landscape. *Nature Immunology*, **2019**, 20, 493-502	19.1	62
130	Taming a beast: lessons from the domestication of hepatitis C virus. *Current Opinion in Virology*, **2019**, 35, 27-34	7.5	6
129	Risk of Zika microcephaly correlates with features of maternal antibodies. *Journal of Experimental Medicine*, **2019**, 216, 2302-2315	16.6	28
128	Replicons of a Rodent Hepatitis C Model Virus Permit Selection of Highly Permissive Cells. *Journal of Virology*, **2019**, 93,	6.6	6

127	Inherited IFNAR1 deficiency in otherwise healthy patients with adverse reaction to measles and yellow fever live vaccines. *Journal of Experimental Medicine*, **2019**, 216, 2057-2070	16.6	77
126	Investigating the functional link between TMEM165 and SPCA1. *Biochemical Journal*, **2019**, 476, 3281-3293	3.8	6
125	Visualization of Positive and Negative Sense Viral RNA for Probing the Mechanism of Direct-Acting Antivirals against Hepatitis C Virus. *Viruses*, **2019**, 11,	6.2	5
124	IFITM3 directly engages and shuttles incoming virus particles to lysosomes. *Nature Chemical Biology* , **2019**, 15, 259-268	11.7	107
123	Antiviral resistance of stem cells. *Current Opinion in Immunology*, **2019**, 56, 50-59	7.8	12
122	Stem Cell-Derived Culture Models of Hepatitis E Virus Infection. *Cold Spring Harbor Perspectives in Medicine*, **2019**, 9,	5.4	8
121	Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies. *Virus Research*, **2018**, 248, 53-62	6.4	95
120	Human ADAR1 Prevents Endogenous RNA from Triggering Translational Shutdown. *Cell*, **2018**, 172, 811-824.e14	56.2	125
119	Genetic Variation at IFNL4 Influences Extrahepatic Interferon-Stimulated Gene Expression in Chronic HCV Patients. *Journal of Infectious Diseases*, **2018**, 217, 650-655	7	14
118	Pan-Genotype Hepatitis E Virus Replication in Stem Cell-Derived Hepatocellular Systems. *Gastroenterology*, **2018**, 154, 663-674.e7	13.3	24
117	Interferon-Stimulated Gene (ISG)-Expression Screening Reveals the Specific Antibunyaviral Activity of ISG20. *Journal of Virology*, **2018**, 92,	6.6	23
116	Viral persistence, liver disease, and host response in a hepatitis C-like virus rat model. *Hepatology*, **2018**, 68, 435-448	11.2	38
115	Control of Human Hemoglobin Switching By LIN28B-Mediated Regulation of BCL11A Translation. *Blood*, **2018**, 132, 412-412	2.2	
114	Identification, Isolation and Transcriptome Analyses of Mouse, Rat and Man Erythroblastic Island Central Macrophages. *Blood*, **2018**, 132, 841-841	2.2	
113	Intrinsic Immunity Shapes Viral Resistance of Stem Cells. *Cell*, **2018**, 172, 423-438.e25	56.2	160
112	Identification of a Small Interface between the Methyltransferase and RNA Polymerase of NS5 that is Essential for Zika Virus Replication. *Scientific Reports*, **2018**, 8, 17384	4.9	8
111	Long-Term Expansion of Functional Mouse and Human Hepatocytes as 3D Organoids. *Cell*, **2018**, 175, 1591-1606.e19	56.2	268
110	T time for ADAR: ADAR1 is required for T cell self-tolerance. *EMBO Reports*, **2018**, 19,	6.5	4

109	A Combination of Two Human Monoclonal Antibodies Prevents Zika Virus Escape Mutations in Non-human Primates. *Cell Reports*, **2018**, 25, 1385-1394.e7	10.6	43
108	NS5A Promotes Constitutive Degradation of IP3R3 to Counteract Apoptosis Induced by Hepatitis C Virus. *Cell Reports*, **2018**, 25, 833-840.e3	10.6	12
107	Friend and foe, HNRNPC takes on immunostimulatory RNAs in breast cancer cells. *EMBO Journal*, **2018**, 37,	13	8
106	New Parvovirus Associated with Serum Hepatitis in Horses after Inoculation of Common Biological Product. *Emerging Infectious Diseases*, **2018**, 24, 303-310	10.2	47
105	Longitudinal transcriptomic characterization of the immune response to acute hepatitis C virus infection in patients with spontaneous viral clearance. *PLoS Pathogens*, **2018**, 14, e1007290	7.6	18
104	Male germ cells support long-term propagation of Zika virus. *Nature Communications*, **2018**, 9, 2090	17.4	44
103	Internal Disequilibria and Phenotypic Diversification during Replication of Hepatitis C Virus in a Noncoevolving Cellular Environment. *Journal of Virology*, **2017**, 91,	6.6	32
102	Single-molecule imaging reveals the translocation and DNA looping dynamics of hepatitis C virus NS3 helicase. *Protein Science*, **2017**, 26, 1391-1403	6.3	13
101	Tumor Necrosis Factor Inhibits Spread of Hepatitis C Virus Among Liver Cells, Independent From Interferons. *Gastroenterology*, **2017**, 153, 566-578.e5	13.3	11
100	Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico. *Cell*, **2017**, 169, 597-609.e11	30.2	199
99	The IFN-λIFN-Rλ1-IL-10Rβ Complex Reveals Structural Features Underlying Type III IFN Functional Plasticity. *Immunity*, **2017**, 46, 379-392	32.3	59
98	Green fluorescent protein-tagged apolipoprotein E: A useful marker for the study of hepatic lipoprotein egress. *Traffic*, **2017**, 18, 192-204	5.7	5
97	Global mapping of miRNA-target interactions in cattle (Bos taurus). *Scientific Reports*, **2017**, 7, 8190	4.9	15
96	Differential Regulation of Lipoprotein and Hepatitis C Virus Secretion by Rab1b. *Cell Reports*, **2017**, 21, 431-441	10.6	21
95	Diverse Viruses Require the Calcium Transporter SPCA1 for Maturation and Spread. *Cell Host and Microbe*, **2017**, 22, 460-470.e5	23.4	33
94	TRIM25 Enhances the Antiviral Action of Zinc-Finger Antiviral Protein (ZAP). *PLoS Pathogens*, **2017**, 13, e1006145	7.6	108
93	Development of a recombinant yellow fever vector expressing a HIV clade C founder envelope gp120. *Journal of Virological Methods*, **2017**, 249, 85-93	2.6	2
92	Argonaute CLIP Defines a Deregulated miR-122-Bound Transcriptome that Correlates with Patient Survival in Human Liver Cancer. *Molecular Cell*, **2017**, 67, 400-410.e7	17.6	50

91	Mouse models of acute and chronic hepacivirus infection. *Science*, **2017**, 357, 204-208	33.3	74
90	In situ expansion of engineered human liver tissue in a mouse model of chronic liver disease. *Science Translational Medicine*, **2017**, 9,	17.5	99
89	A robust cell culture system supporting the complete life cycle of hepatitis B virus. *Scientific Reports*, **2017**, 7, 16616	4.9	37
88	Effects of amino acid substitutions in hepatitis B virus surface protein on virion secretion, antigenicity, HBsAg and viral DNA. *Journal of Hepatology*, **2017**, 66, 288-296	13.4	50
87	A Freeze Drying Sample Preparation Method for Correlative Light and Scanning/Transmission Electron Microscopy. *Microscopy and Microanalysis*, **2017**, 23, 1368-1369	0.5	
86	Freeze Drying Method with Gaseous Nitrogen for Biological Application of Helium Ion Microcopy. *Microscopy and Microanalysis*, **2017**, 23, 1370-1371	0.5	1
85	miRNA independent hepacivirus variants suggest a strong evolutionary pressure to maintain miR-122 dependence. *PLoS Pathogens*, **2017**, 13, e1006694	7.6	18
84	Loss of Sendai virus C protein leads to accumulation of RIG-I immunostimulatory defective interfering RNA. *Journal of General Virology*, **2017**, 98, 1282-1293	4.9	18
83	Tuning a cellular lipid kinase activity adapts hepatitis C virus to replication in cell culture. *Nature Microbiology*, **2016**, 2, 16247	26.6	39
82	Identification of Interferon-Stimulated Genes with Antiretroviral Activity. *Cell Host and Microbe*, **2016**, 20, 392-405	23.4	126
81	Hepatitis C Virus-From Discovery to Cure: The 2016 Lasker-DeBakey Clinical Medical Research Award. *JAMA - Journal of the American Medical Association*, **2016**, 316, 1254-5	27.4	2
80	Expanding the Host Range of Hepatitis C Virus through Viral Adaptation. *MBio*, **2016**, 7,	7.8	8
79	Reply. *Gastroenterology*, **2016**, 150, 1690-1691	13.3	
78	Chaperone-Assisted Protein Folding Is Critical for Yellow Fever Virus NS3/4A Cleavage and Replication. *Journal of Virology*, **2016**, 90, 3212-28	6.6	20
77	Proteomics of HCV virions reveals an essential role for the nucleoporin Nup98 in virus morphogenesis. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 2484-9	11.5	52
76	A Broad RNA Virus Survey Reveals Both miRNA Dependence and Functional Sequestration. *Cell Host and Microbe*, **2016**, 19, 409-23	23.4	82
75	Sofosbuvir Inhibits Hepatitis E Virus Replication In Vitro and Results in an Additive Effect When Combined With Ribavirin. *Gastroenterology*, **2016**, 150, 82-85.e4	13.3	130
74	Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir. *PLoS ONE*, **2016**, 11, e0164691	3.7	46

73	The Spring-Helix Coordinates Multiple Modes of HCV (Hepatitis C Virus) NS3 Helicase Action. *Journal of Biological Chemistry*, **2016**, 291, 14499-509	5.4	8
72	Interferon regulatory factor 2 protects mice from lethal viral neuroinvasion. *Journal of Experimental Medicine*, **2016**, 213, 2931-2947	16.6	6
71	Freeze Drying Method with Gaseous Nitrogen to Preserve Fine Ultrastructure of Biological Organizations for Scanning Electron Microscopy, Helium Ion Beam Microscopy and Fluorescence Microscopy. *Microscopy and Microanalysis*, **2016**, 22, 1142-1143	0.5	3
70	Present and not reporting for duty: dsRNAi in mammalian cells. *EMBO Journal*, **2016**, 35, 2499-2501	13	4
69	Superior In vivo Transduction of Human Hepatocytes Using Engineered AAV3 Capsid. *Molecular Therapy*, **2016**, 24, 1042-1049	11.7	65
68	Barrier-Independent, Fitness-Associated Differences in Sofosbuvir Efficacy against Hepatitis C Virus. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 3786-93	5.9	29
67	Humanized mice efficiently engrafted with fetal hepatoblasts and syngeneic immune cells develop human monocytes and NK cells. *Journal of Hepatology*, **2016**, 65, 334-43	13.4	53
66	Viral genome imaging of hepatitis C virus to probe heterogeneous viral infection and responses to antiviral therapies. *Virology*, **2016**, 494, 236-47	3.6	14
65	Interferons and viruses: an evolutionary arms race of molecular interactions. *Trends in Immunology*, **2015**, 36, 124-38	14.4	243
64	Hepatitis C virus RNA functionally sequesters miR-122. *Cell*, **2015**, 160, 1099-110	56.2	246
63	Identification, molecular cloning, and analysis of full-length hepatitis C virus transmitted/founder genotypes 1, 3, and 4. *MBio*, **2015**, 6, e02518	7.8	13
62	Interferon-regulates cellular metabolism and mRNA translation to potentiate macrophage activation. *Nature Immunology*, **2015**, 16, 838-849	19.1	175
61	ATP-dependent effector-like functions of RIG-I-like receptors. *Molecular Cell*, **2015**, 58, 541-548	17.6	55
60	To translate, or not to translate: viral and host mRNA regulation by interferon-stimulated genes. *Trends in Cell Biology*, **2015**, 25, 320-9	18.3	54
59	Hepatitis C virus infects rhesus macaque hepatocytes and simianized mice. *Hepatology*, **2015**, 62, 57-67	11.2	16
58	Fast hepatitis C virus RNA elimination and NS5A redistribution by NS5A inhibitors studied by a multiplex assay approach. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 3482-92	5.9	19
57	SEC14L2 enables pan-genotype HCV replication in cell culture. *Nature*, **2015**, 524, 471-5	50.4	88
56	miRNA-target chimeras reveal miRNA 3Rend pairing as a major determinant of Argonaute target specificity. *Nature Communications*, **2015**, 6, 8864	17.4	179

55	Micropatterned coculture of primary human hepatocytes and supportive cells for the study of hepatotropic pathogens. *Nature Protocols*, **2015**, 10, 2027-53	18.8	92
54	The RNA sensor RIG-I dually functions as an innate sensor and direct antiviral factor for hepatitis B virus. *Immunity*, **2015**, 42, 123-32	32.3	279
53	Repurposing an old drug: A low-cost allergy medication provides new hope for hepatitis C patients. *Hepatology*, **2015**, 62, 1911-3	11.2	3
52	Screening of the Pan-African natural product library identifies ixoratannin A-2 and boldine as novel HIV-1 inhibitors. *PLoS ONE*, **2015**, 10, e0121099	3.7	32
51	CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus. *Scientific Reports*, **2015**, 5, 10833	4.9	205
50	Hepatitis B virus induces RNR-R2 expression via DNA damage response activation. *Journal of Hepatology*, **2015**, 63, 789-96	13.4	21
49	Quantitative Proteomics Identifies Serum Response Factor Binding Protein 1 as a Host Factor for Hepatitis C Virus Entry. *Cell Reports*, **2015**, 12, 864-78	10.6	40
48	A serpin shapes the extracellular environment to prevent influenza A virus maturation. *Cell*, **2015**, 160, 631-643	56.2	90
47	Characterization of nonprimate hepacivirus and construction of a functional molecular clone. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 2192-7	11.5	72
46	In memoriam--Richard M. Elliott (1954-2015). *Journal of General Virology*, **2015**, 96, 1975-1978	4.9	2
45	Identification of AP80978, a novel small-molecule inhibitor of hepatitis C virus replication that targets NS4B. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 3399-410	5.9	18
44	Interferon-stimulated genes: a complex web of host defenses. *Annual Review of Immunology*, **2014**, 32, 513-45	34.7	1593
43	Interferon lambda alleles predict innate antiviral immune responses and hepatitis C virus permissiveness. *Cell Host and Microbe*, **2014**, 15, 190-202	23.4	82
42	Host-cell sensors for Plasmodium activate innate immunity against liver-stage infection. *Nature Medicine*, **2014**, 20, 47-53	50.5	186
41	Pan-viral specificity of IFN-induced genes reveals new roles for cGAS in innate immunity. *Nature*, **2014**, 505, 691-5	50.4	600
40	Hepatitis C virus genotype 5a subgenomic replicons for evaluation of direct-acting antiviral agents. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 5386-94	5.9	28
39	Seed sequence-matched controls reveal limitations of small interfering RNA knockdown in functional and structural studies of hepatitis C virus NS5A-MOBKL1B interaction. *Journal of Virology*, **2014**, 88, 11022-33	6.6	18
38	Increased replicative fitness can lead to decreased drug sensitivity of hepatitis C virus. *Journal of Virology*, **2014**, 88, 12098-111	6.6	57

37	Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma. *Seminars in Cancer Biology*, **2014**, 26, 78-88	12.7	119
36	Modeling host interactions with hepatitis B virus using primary and induced pluripotent stem cell-derived hepatocellular systems. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 12193-8	11.5	183
35	Hepatitis C: Treatment triumphs. *Nature*, **2014**, 510, 43-4	50.4	32
34	New Methods in Tissue Engineering: Improved Models for Viral Infection. *Annual Review of Virology* , **2014**, 1, 475-499	14.6	20
33	Multifaceted activities of type I interferon are revealed by a receptor antagonist. *Science Signaling*, **2014**, 7, ra50	8.8	65
32	Broadly neutralizing antibodies abrogate established hepatitis C virus infection. *Science Translational Medicine*, **2014**, 6, 254ra129	17.5	161
31	The ins and outs of hepatitis C virus entry and assembly. *Nature Reviews Microbiology*, **2013**, 11, 688-700	22.2	261
30	Recapitulation of the hepatitis C virus life-cycle in engineered murine cell lines. *Virology*, **2013**, 444, 1-11	3.6	45
29	Identification of rodent homologs of hepatitis C virus and pegiviruses. *MBio*, **2013**, 4, e00216-13	7.8	146
28	Different requirements for scavenger receptor class B type I in hepatitis C virus cell-free versus cell-to-cell transmission. *Journal of Virology*, **2013**, 87, 8282-93	6.6	63
27	Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1). *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 15001-6	11.5	134
26	Identification of a pegivirus (GB virus-like virus) that infects horses. *Journal of Virology*, **2013**, 87, 7185-90	6.6	73
25	Dengue reporter viruses reveal viral dynamics in interferon receptor-deficient mice and sensitivity to interferon effectors in vitro. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 14610-5	11.5	140
24	Serology-enabled discovery of genetically diverse hepaciviruses in a new host. *Journal of Virology*, **2012**, 86, 6171-8	6.6	183
23	Characterization of a canine homolog of hepatitis C virus. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 11608-13	11.5	208
22	A diverse range of gene products are effectors of the type I interferon antiviral response. *Nature*, **2011**, 472, 481-5	50.4	1584
21	Expression of paramyxovirus V proteins promotes replication and spread of hepatitis C virus in cultures of primary human fetal liver cells. *Hepatology*, **2011**, 54, 1901-12	11.2	74
20	Perspective: miles to go before we sleep. *Nature*, **2011**, 474, S8	50.4	16

19	Identification and characterization of the host protein DNAJC14 as a broadly active flavivirus replication modulator. *PLoS Pathogens*, **2011**, 7, e1001255	7.6	60
18	Real-time imaging of hepatitis C virus infection using a fluorescent cell-based reporter system. *Nature Biotechnology*, **2010**, 28, 167-71	44.5	201
17	Chair's Introduction. *Novartis Foundation Symposium*, **2008**, 1-2		
16	Hepatitis C virus p7 and NS2 proteins are essential for production of infectious virus. *Journal of Virology*, **2007**, 81, 8374-83	6.6	358
15	Complete replication of hepatitis C virus in cell culture. *Science*, **2005**, 309, 623-6	33.3	1904
14	Treating hepatitis C: can you teach old dogs new tricks?. *Hepatology*, **2005**, 42, 1455-8	11.2	16
13	HCV persistence and immune evasion in the absence of memory T cell help. *Science*, **2003**, 302, 659-62	33.3	669
12	A stable full-length yellow fever virus cDNA clone and the role of conserved RNA elements in flavivirus replication. *Journal of General Virology*, **2003**, 84, 1261-1268	4.9	163
11	Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. *Journal of Virology*, **2002**, 76, 13001-14	6.6	984
10	Bad time for Bonzo? Experimental models of hepatitis C virus infection, replication, and pathogenesis. *Hepatology*, **2001**, 33, 489-95	11.2	37
9	Cis-acting RNA elements at the 5' end of Sindbis virus genome RNA regulate minus- and plus-strand RNA synthesis. *Rna*, **2001**, 7, 1638-51	5.8	101
8	Efficient initiation of HCV RNA replication in cell culture. *Science*, **2000**, 290, 1972-4	33.3	1221
7	Is CD81 the key to hepatitis C virus entry?. *Hepatology*, **1999**, 29, 990-2	11.2	23
6	Continuous human cell lines inducibly expressing hepatitis C virus structural and nonstructural proteins. *Hepatology*, **1998**, 28, 192-201	11.2	138
5	cis-acting RNA elements required for replication of bovine viral diarrhea virus-hepatitis C virus 5' nontranslated region chimeras. *Rna*, **1998**, 4, 1418-35	5.8	61
4	Infectious bovine viral diarrhea virus (strain NADL) RNA from stable cDNA clones: a cellular insert determines NS3 production and viral cytopathogenicity. *Journal of Virology*, **1998**, 72, 4737-45	6.6	121
3	Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. *Science*, **1997**, 277, 570-4	33.3	586
2	Complete nucleotide sequence of yellow fever virus vaccine strains 17DD and 17D-213. *Virus Research*, **1995**, 35, 35-41	6.4	71

1	Flavivirus genome organization, expression, and replication. *Annual Review of Microbiology*, **1990**, 44, 649-88	17.5	1491